INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-07-29
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, dose-escalation/dose-expansion Phase 1 clinical study to
investigate the safety, tolerability, PK profile, pharmacodynamics, and preliminary clinical
efficacy of INCB106385 when given as monotherapy or in combination with INCMGA00012 in
participants with selected CD8 T-cell-positive advanced solid tumors including SCCHN, NSCLC,
ovarian cancer, CRPC, TNBC, or bladder cancer